Cited 0 times in
Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신재일 | - |
dc.contributor.author | 임범진 | - |
dc.date.accessioned | 2024-01-03T01:02:17Z | - |
dc.date.available | 2024-01-03T01:02:17Z | - |
dc.date.issued | 2023-07 | - |
dc.identifier.issn | 0021-9746 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/197440 | - |
dc.description.abstract | Aim: The prognostic role of CD274 (programmed cell death ligand 1 (PD-L1)) overexpression has been examined in many studies. However, the results are controversial and conflicting. The present study aims to investigate the potential role of CD274 (PD-L1) immunohistochemical overexpression as a prognostic marker in malignant tumours. Methods: We searched PubMed, Embase and Web of Science from inception to December 2021 to identify potentially eligible studies. The pooled HRs with 95% CIs were calculated to identify the association between CD274 (PD-L1) overexpression and overall survival (OS), cancer-specific survival, disease-free survival, recurrence-free survival and progression-free survival in 10 lethal malignant tumours. Heterogeneity and publication bias were also analysed. Results: The study included 57 322 patients from 250 eligible studies (241 articles). The meta-analysis by tumour type using multivariate HR revealed worse OS in non-small cell lung cancer (HR 1.41, 95% CI 1.19 to 1.68), hepatocellular carcinoma (HR 1.75, 95% CI 1.11 to 2.74), pancreatic cancer (HR 1.84, 95% CI 1.12 to 3.02), renal cell carcinoma (HR 1.55, 95% CI 1.12 to 2.14) and colorectal cancer (HR 1.46, 95% CI 1.14 to 1.88). Estimated HRs showed associations between CD274 (PD-L1) overexpression and worse prognosis across different types of tumours in various survival endpoints, but no inverse correlation was identified. The heterogeneity for most of the pooled results was high. Conclusions: This large meta-analysis suggests that CD274 (PD-L1) overexpression is a potential biomarker for multiple types of cancers. However, further studies are needed to reduce high heterogeneity. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | BMJ Pub. Group | - |
dc.relation.isPartOf | JOURNAL OF CLINICAL PATHOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | B7-H1 Antigen / analysis | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Kidney Neoplasms* | - |
dc.subject.MESH | Liver Neoplasms* | - |
dc.subject.MESH | Lung Neoplasms* | - |
dc.subject.MESH | Prognosis | - |
dc.title | Effect of CD274 (PD-L1) overexpression on survival outcomes in 10 specific cancers: a systematic review and meta-analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Pediatrics (소아과학교실) | - |
dc.contributor.googleauthor | Ji Hyun Park | - |
dc.contributor.googleauthor | Claudio Luchini | - |
dc.contributor.googleauthor | Alessia Nottegar | - |
dc.contributor.googleauthor | Kalthoum Tizaoui | - |
dc.contributor.googleauthor | Ai Koyanagi | - |
dc.contributor.googleauthor | Shuji Ogino | - |
dc.contributor.googleauthor | Jae Il Shin | - |
dc.contributor.googleauthor | Beom Jin Lim | - |
dc.contributor.googleauthor | Lee Smith | - |
dc.identifier.doi | 10.1136/jcp-2023-208848 | - |
dc.contributor.localId | A02142 | - |
dc.contributor.localId | A03363 | - |
dc.relation.journalcode | J01334 | - |
dc.identifier.eissn | 1472-4146 | - |
dc.identifier.pmid | 37130750 | - |
dc.identifier.url | https://jcp.bmj.com/content/76/7/450 | - |
dc.subject.keyword | IMMUNOHISTOCHEMISTRY | - |
dc.subject.keyword | Medical Oncology | - |
dc.subject.keyword | NEOPLASMS | - |
dc.contributor.alternativeName | Shin, Jae Il | - |
dc.contributor.affiliatedAuthor | 신재일 | - |
dc.contributor.affiliatedAuthor | 임범진 | - |
dc.citation.volume | 76 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 450 | - |
dc.citation.endPage | 456 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CLINICAL PATHOLOGY, Vol.76(7) : 450-456, 2023-07 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.